Low-dose infigratinib increases bone growth and corrects growth plate abnormalities in an achondroplasia mouse model.

Autor: Demuynck B; Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, INSERM UMR1163, Université de Paris Cité, Imagine Institute, Paris, France., Flipo J; Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, INSERM UMR1163, Université de Paris Cité, Imagine Institute, Paris, France., Kaci N; Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, INSERM UMR1163, Université de Paris Cité, Imagine Institute, Paris, France., Dambkowski C; QED Therapeutics, San Francisco, CA 94107, United States., Paull M; QED Therapeutics, San Francisco, CA 94107, United States., Muslimova E; QED Therapeutics, San Francisco, CA 94107, United States., Shah BP; QED Therapeutics, San Francisco, CA 94107, United States., Legeai-Mallet L; Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, INSERM UMR1163, Université de Paris Cité, Imagine Institute, Paris, France.

Publikováno v: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research [J Bone Miner Res] 2024 Jul 23; Vol. 39 (6), pp. 765-774.

Infigratinib, a selective FGFR1-3 tyrosine kinase inhibitor, alters dentoalveolar development at high doses.

Autor: Michel ZD; Skeletal Disorders and Mineral Homeostasis Section, National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), Bethesda, Maryland, USA., Aitken SF; Laboratory of Oral Connective Tissue Biology, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health, Bethesda, Maryland, USA., Glover OD; Laboratory of Oral Connective Tissue Biology, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health, Bethesda, Maryland, USA., Alejandro LO; Laboratory of Oral Connective Tissue Biology, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health, Bethesda, Maryland, USA., Randazzo D; Light Imaging Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, Maryland, USA., Dambkowski C; QED Therapeutics, San Francisco, California, USA., Martin D; QED Therapeutics, San Francisco, California, USA., Collins MT; Skeletal Disorders and Mineral Homeostasis Section, National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), Bethesda, Maryland, USA., Somerman MJ; Laboratory of Oral Connective Tissue Biology, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health, Bethesda, Maryland, USA., Chu EY; Laboratory of Oral Connective Tissue Biology, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health, Bethesda, Maryland, USA.; Department of Comprehensive Dentistry, Division of Cariology and Operative Dentistry, University of Maryland School of Dentistry, Baltimore, Maryland, USA.

Publikováno v: Developmental dynamics : an official publication of the American Association of Anatomists [Dev Dyn] 2023 Dec; Vol. 252 (12), pp. 1428-1448. Date of Electronic Publication: 2023 Jul 12.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pre-bariatric surgery weight loss requirements and the effect of preoperative weight loss on postoperative outcome.

Autor: Ochner, C N¹, Dambkowski, C L², Yeomans, B L², Teixeira, J³, Xavier Pi-Sunyer, F²

Publikováno v: International Journal of Obesity. Nov2012, Vol. 36 Issue 11, p1380-1387. 8p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.